PMID- 15951473
OWN - NLM
STAT- MEDLINE
DCOM- 20051103
LR  - 20181201
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 45
IP  - 7
DP  - 2005 Jul
TI  - An evaluation of an optimal sampling strategy for meropenem in febrile 
      neutropenics.
PG  - 832-5
AB  - Optimal sampling design with nonparametric population modeling offers the 
      opportunity to determine pharmacokinetic parameters for patients in whom blood 
      sampling is restricted. This approach was compared to a standard individualized 
      modeling method for meropenem pharmacokinetics in febrile neutropenic patients. 
      The population modeling program, nonparametric approach of expectation 
      maximization (NPEM), with a full data set was compared to a sparse data set 
      selected by D-optimal sampling design. The authors demonstrated that the 
      D-optimal sampling strategy, when applied to this clinical population, provided 
      good pharmacokinetic parameter estimates along with their variability. Four 
      individualized and optimally selected sampling time points provided the same 
      parameter estimates as more intensive sampling regimens using traditional and 
      population modeling techniques. The different modeling methods were considerably 
      consistent, except for the estimation of CL(d) with sparse sampling. The findings 
      suggest that D-optimal sparse sampling is a reasonable approach to population 
      pharmacokinetic/pharmacodynamic studies during drug development when limited 
      sampling is necessary.
FAU - Ariano, Robert E
AU  - Ariano RE
AD  - Department of Pharmacy, St. Boniface General Hospital, Winnipeg, Manitoba, 
      Canada.
FAU - Zelenitsky, Sheryl A
AU  - Zelenitsky SA
FAU - Nyhlen, Anna
AU  - Nyhlen A
FAU - Sitar, Daniel S
AU  - Sitar DS
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Thienamycins)
RN  - AYI8EX34EU (Creatinine)
RN  - FV9J3JU8B1 (Meropenem)
SB  - IM
MH  - Anti-Bacterial Agents/*pharmacokinetics
MH  - Creatinine/metabolism
MH  - Female
MH  - Fever/metabolism
MH  - Humans
MH  - Male
MH  - Meropenem
MH  - Metabolic Clearance Rate
MH  - Middle Aged
MH  - *Models, Biological
MH  - Neutropenia/*metabolism
MH  - Research Design
MH  - Thienamycins/*pharmacokinetics
EDAT- 2005/06/14 09:00
MHDA- 2005/11/04 09:00
CRDT- 2005/06/14 09:00
PHST- 2005/06/14 09:00 [pubmed]
PHST- 2005/11/04 09:00 [medline]
PHST- 2005/06/14 09:00 [entrez]
AID - 45/7/832 [pii]
AID - 10.1177/0091270005277937 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2005 Jul;45(7):832-5. doi: 10.1177/0091270005277937.